MA31264B1 - Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison - Google Patents

Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Info

Publication number
MA31264B1
MA31264B1 MA32234A MA32234A MA31264B1 MA 31264 B1 MA31264 B1 MA 31264B1 MA 32234 A MA32234 A MA 32234A MA 32234 A MA32234 A MA 32234A MA 31264 B1 MA31264 B1 MA 31264B1
Authority
MA
Morocco
Prior art keywords
combination
human
methods
treating cancer
administering human
Prior art date
Application number
MA32234A
Other languages
Arabic (ar)
English (en)
Inventor
Zdenka Haskova
Zdenka Ludmila Jonak
Stephen H Trulli
Margaret N Whitacre
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39788932&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA31264(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of MA31264B1 publication Critical patent/MA31264B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Mycology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Toxicology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La présente invention concerne d'une manière générale l'utilisation de l'il-18 humaine en combinaison dans le traitement de diverses formes de tumeurs solides et de lymphomes. Cette invention concerne en particulier (1) l'utilisation de l'il-18 humaine combinée à des anticorps monoclonaux dirigés contre des antigènes exprimés sur la surface de cellules cancéreuses; et (2) l'utilisation de l'il-18 humaine combinée à des agents chimiothérapeutiques.
MA32234A 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison MA31264B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US89685507P 2007-03-23 2007-03-23
US95200207P 2007-07-26 2007-07-26
PCT/US2008/057615 WO2008118733A2 (fr) 2007-03-23 2008-03-20 Méthodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison

Publications (1)

Publication Number Publication Date
MA31264B1 true MA31264B1 (fr) 2010-03-01

Family

ID=39788932

Family Applications (2)

Application Number Title Priority Date Filing Date
MA32234A MA31264B1 (fr) 2007-03-23 2009-09-24 Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
MA32235A MA31265B1 (fr) 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20

Family Applications After (1)

Application Number Title Priority Date Filing Date
MA32235A MA31265B1 (fr) 2007-03-23 2009-09-24 Traitement du cancer au moyen de l'il-18 humaine combinee a un anticorps anti-cd20

Country Status (21)

Country Link
US (4) US20080274078A1 (fr)
EP (3) EP2136841A4 (fr)
JP (2) JP2010522200A (fr)
KR (2) KR20100014530A (fr)
CN (1) CN101678102A (fr)
AR (2) AR065803A1 (fr)
AU (2) AU2008231025A1 (fr)
BR (2) BRPI0809079A2 (fr)
CA (2) CA2681851A1 (fr)
CL (2) CL2008000818A1 (fr)
CR (2) CR10996A (fr)
DO (2) DOP2009000208A (fr)
EA (2) EA200970885A1 (fr)
IL (2) IL200525A0 (fr)
MA (2) MA31264B1 (fr)
MX (2) MX2009010271A (fr)
NZ (1) NZ579179A (fr)
PE (2) PE20090190A1 (fr)
SG (1) SG171674A1 (fr)
TW (2) TW200906436A (fr)
WO (2) WO2008118733A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI373343B (en) * 2000-02-10 2012-10-01 Abbott Gmbh & Co Kg Antibodies that bind human interleukin-18 and methods of making and using
US7968684B2 (en) 2003-11-12 2011-06-28 Abbott Laboratories IL-18 binding proteins
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento
TW201302793A (zh) 2010-09-03 2013-01-16 Glaxo Group Ltd 新穎之抗原結合蛋白
HUE047952T2 (hu) 2014-04-25 2020-05-28 Pf Medicament Ellenanyag-drog konjugátum és alkalmazása rák kezelésében történõ alkalmazásra
BR112016024619A2 (pt) 2014-04-25 2017-10-10 Pf Medicament conjugado de anticorpo ao igf-1r-fármaco e seu uso para o tratamento de câncer
CA2957387A1 (fr) * 2014-08-07 2016-02-11 Haruki Okamura Agent therapeutique contre le cancer contenant une combinaison d'il-18 et d'anticorps de ciblage de molecules
WO2016126615A1 (fr) * 2015-02-03 2016-08-11 Armo Biosciences, Inc. Procédés d'utilisation de l'interleukine-10 pour le traitement de maladies et de troubles
WO2022115946A1 (fr) * 2020-12-02 2022-06-09 The Royal Institution For The Advancement Of Learning/Mcgill University Applications thérapeutiques d'antagonistes du récepteur du facteur de croissance de type insuline 1 (igf-1)
WO2025033330A1 (fr) * 2023-08-04 2025-02-13 医療革新国際連携株式会社 Thérapie antitumorale par utilisation combinée d'un inhibiteur de chymase et d'une immunothérapie

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69519454T2 (de) 1994-07-14 2001-05-03 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo, Okayama Protein, das Interferon-Gamma Herstellung induziert und monoklonaler Antikörper dagegen
US7135458B1 (en) * 1995-11-15 2006-11-14 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Interferon-γ inducing polypeptide, pharmaceutical composition thereof, monoclonal antibody thereto, and methods of use
JP4004088B2 (ja) 1995-09-26 2007-11-07 株式会社林原生物化学研究所 免疫担当細胞においてインターフェロン−γの産生を誘導する蛋白質
TW581771B (en) 1994-11-15 2004-04-01 Hayashibara Biochem Lab Recombinant production of a polypeptide for inducing interferon-gamma production, and monoclonal antibody against the polypeptide
US5680795A (en) 1995-07-05 1997-10-28 Norco Inc. Mechanical drive assembly incorporating counter-spring biassed radially-adjustable rollers
JP4024366B2 (ja) * 1996-11-29 2007-12-19 株式会社林原生物化学研究所 ポリペプチド
US6787132B1 (en) * 1997-12-04 2004-09-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Combined chemo-immunotherapy with liposomal drugs and cytokines
TWI227136B (en) * 1998-05-21 2005-02-01 Smithkline Beecham Corp Novel pharmaceutical composition for the prevention and/or treatment of cancer
CZ20024085A3 (cs) 2000-06-15 2003-05-14 Smithkline Beecham Corporation Způsob přípravy fyziologicky aktivního IL-18 polypeptidu
US20020094323A1 (en) * 2000-10-12 2002-07-18 Kristoffer Hellstrand Methods and compositions for promoting the maturation of monocytes
CA2476166C (fr) * 2002-02-14 2011-11-15 Immunomedics, Inc. Anticorps anti-cd20 et proteines hybrides desdits anticorps, et methodes d'utilisation
WO2003072736A2 (fr) * 2002-02-21 2003-09-04 Duke University Reactifs et methodes therapeutiques de maladies auto-immunes
JP4516844B2 (ja) * 2002-09-16 2010-08-04 エイジェニックス インコーポレイテッド 創傷の処置におけるラクトフェリン
EP1558284B1 (fr) * 2002-10-08 2013-09-11 Immunomedics, Inc. Therapie associant des anticorps nus monoclonaux anti-cea de classe iii et des agents therapeutiques
PL216630B1 (pl) * 2002-10-17 2014-04-30 Genmab As Izolowane ludzkie przeciwciało monoklonalne wiążące ludzki CD20, związane z tym przeciwciałem transfektoma, komórka gospodarza, transgeniczne zwierzę lub roślina, kompozycja, immunokoniugat, cząsteczka bispecyficzna, wektor ekspresyjny, kompozycja farmaceutyczna, zastosowanie medyczne, zestaw oraz przeciwciało antyidiotypowe i jego zastosowanie
US7534427B2 (en) * 2002-12-31 2009-05-19 Immunomedics, Inc. Immunotherapy of B cell malignancies and autoimmune diseases using unconjugated antibodies and conjugated antibodies and antibody combinations and fusion proteins
EP2261244A3 (fr) * 2003-04-15 2011-02-23 Glaxosmithkline LLC Mutants par substitution de l'interluekine 18 humaine et ces conjugués
WO2005018542A2 (fr) * 2003-07-10 2005-03-03 Agennix Incorporated Utilisation de lactoferrine dans une prophylaxie dirigee contre une infection et/ou contre une inflammation, chez des patients immunosupprimes
EP2216342B1 (fr) * 2003-07-31 2015-04-22 Immunomedics, Inc. Anticorps anti-CD19
BRPI0609079A2 (pt) * 2005-04-18 2010-11-16 Novo Nordisk As peptìdeo, composição farmacêutica, método para o tratamento de cáncer, uso de um peptìdeo construto de ácido nucleico, vetor, hospedeiro, e, anticorpo
AU2006272204A1 (en) * 2005-07-21 2007-01-25 Genmab A/S Potency assays for antibody drug substance binding to an Fc receptor
EP2368566A1 (fr) * 2006-07-13 2011-09-28 ZymoGenetics, Inc. Combinaison d' interleukine 21 et d'inhibiteur de tyrosine kinase en thérapie
US20100061958A1 (en) * 2006-09-14 2010-03-11 The Trustees Of The University Of Pennsylvania Modulation of Regulatory T Cells by Human IL-18
AR065803A1 (es) * 2007-03-23 2009-07-01 Smithkline Beecham Corp Uso de un polipeptido de il- 18 humana y un anticuerpo anti- cd para preparar unmedicamento

Also Published As

Publication number Publication date
TW200904469A (en) 2009-02-01
PE20090190A1 (es) 2009-03-22
CN101678102A (zh) 2010-03-24
EA200970884A1 (ru) 2010-04-30
AU2008231025A1 (en) 2008-10-02
CR10996A (es) 2009-11-12
EP2338514A1 (fr) 2011-06-29
WO2008118733A3 (fr) 2008-11-27
NZ579179A (en) 2011-12-22
CA2681827A1 (fr) 2008-10-02
AR065803A1 (es) 2009-07-01
EP2136841A2 (fr) 2009-12-30
US20100111945A1 (en) 2010-05-06
EP2129398A1 (fr) 2009-12-09
BRPI0809079A2 (pt) 2019-03-06
WO2008118733A2 (fr) 2008-10-02
MA31265B1 (fr) 2010-03-01
WO2008118736A1 (fr) 2008-10-02
JP2010522200A (ja) 2010-07-01
CA2681851A1 (fr) 2008-10-02
US20090035258A1 (en) 2009-02-05
CL2008000818A1 (es) 2008-09-26
DOP2009000220A (es) 2009-10-31
IL200525A0 (en) 2010-04-29
SG171674A1 (en) 2011-06-29
TW200906436A (en) 2009-02-16
PE20090184A1 (es) 2009-03-22
KR20100015798A (ko) 2010-02-12
MX2009010269A (es) 2009-10-12
US20100196310A1 (en) 2010-08-05
AU2008231114A1 (en) 2008-10-02
EP2129398A4 (fr) 2010-04-21
CL2008000842A1 (es) 2008-10-17
DOP2009000208A (es) 2010-03-31
IL200863A0 (en) 2010-05-17
JP2010522239A (ja) 2010-07-01
BRPI0808943A2 (pt) 2014-08-26
AR065818A1 (es) 2009-07-01
US20080274078A1 (en) 2008-11-06
EA200970885A1 (ru) 2010-02-26
KR20100014530A (ko) 2010-02-10
CR11075A (es) 2010-03-22
MX2009010271A (es) 2009-10-12
EP2136841A4 (fr) 2010-07-07

Similar Documents

Publication Publication Date Title
MA31264B1 (fr) Methodes de traitement du cancer comprenant l'administration de l'il-18 humaine en combinaison
EA201300246A1 (ru) Ингибиторы тирозинкиназы брутона
MA31862B1 (fr) Anticorps anti-mésothéline et leurs utilisations
BRPI0507684A (pt) agentes de contraste para formação de imagem de perfusão miocárdica
EP1844077A4 (fr) Anticorps dr5 et utilisations de ceux-ci
Morad et al. Tamoxifen magnifies therapeutic impact of ceramide in human colorectal cancer cells independent of p53
MA31205B1 (fr) Combinaisons d'agents therapeutiques pour le traitement du cancer
MA35056B1 (fr) Stratification à base de bcma et traitement pour patients atteints de myélome multiple
UA105760C2 (uk) Антитіло проти bst2
MA33323B1 (fr) Thérapie adjuvante de cancer
Emmenegger et al. Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice
MA33839B1 (fr) Compositions et procédés destinés à diagnostiquer et à traiter des tumeurs
MA33091B1 (fr) Combinaisons pharmaceutiques comprenant rdea119/bay 869766 pour le traitement de cancers specifiques
UA93004C2 (ru) Композиция для вагинального применения
MA29587B1 (fr) Compositions et methodes de diagnostic et de traitement de tumeur
WO2006038212A3 (fr) Methodes et compositions de diagnostic et de traitement du cancer
MA33913B1 (fr) Utilisation thérapeutique de conjugues proteines-polymeres
TW200615000A (en) Use of arginase for the treatment of hepatitis